Royalty Pharma (RPRX) Other financing activities (2020 - 2026)

Royalty Pharma has reported Other financing activities for 4 years, with the latest figure at -$226000.0 in Q1 2026.

• Quarterly Other financing activities changed N/A year-over-year to -$226000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$2.0 million (down 201700.0% YoY) and the FY2025 annual result came in at -$1.8 million, up 80.17% from the prior year.
• Other financing activities grew to -$226000.0 in Q1 2026 per RPRX's latest filing, from -$1.8 million in the prior quarter.
• Over five years, Other financing activities peaked at $2000.0 in Q3 2024 and troughed at -$1.8 million in Q4 2025.
• A 3-year average of -$503750.0 and a median of -$113500.0 in 2024 frame the typical range for Other financing activities.
• The widest YoY moves for Other financing activities: up 178900.0% in 2025, down 178900.0% in 2025.
• Over 3 years, Other financing activities stood at -$1000.0 in 2024, then slumped by 178900.0% to -$1.8 million in 2025, then surged by 87.37% to -$226000.0 in 2026.
• According to Business Quant data, Other financing activities over the past three periods registered -$226000.0, -$1.8 million, and -$1000.0 for Q1 2026, Q4 2025, and Q4 2024 respectively.